# Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

> **NCT00905398** · PHASE1,PHASE2 · TERMINATED · sponsor: **Rony Schaffel** · enrollment: 8 (actual)

## Conditions studied

- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Nilotinib

## Key facts

- **NCT ID:** NCT00905398
- **Lead sponsor:** Rony Schaffel
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-05
- **Primary completion:** 2012-06
- **Final completion:** 2015-07
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** The study was terminated due to excessive toxicity and low compliance to the protocol scheme.
- **Last updated:** 2015-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00905398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00905398, "Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00905398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*